NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place December 1-4, 2025, in ...

Group 1 - The article highlights significant declines in the stock prices of several Chinese concept stocks, with Dreamland experiencing the largest drop of 80.98% [1] - Other notable declines include Tianruixiang at 46.5%, Zhiling Group at 29.96%, and Mercurity Fintech at 26.69% [1] - The trading volumes for these stocks varied, with Dreamland having a transaction amount of 37.5017 million and Mercurity Fintech at 8.0682 million [1] Group 2 - Dreamland's latest price is reported at 1.160, down by 4.940 [1] - Tianruixiang's latest price is 1.260, down by 1.095 [1] - Zhiling Group's latest price is 1.660, down by 0.710 [1]

$2 million upfront with up to additional $4 million of potential aggregate gross proceeds upon the exercise in full of warrants NEW YORK, NY, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it has entered into definitive agreements for the purchase and sale of 1,000,000 Class A ordinary shares at a purchase price of $2.00 per share in a registered ...

Core Viewpoint - Aptorum Group Limited announces the addition of Dr. Laura A. Philips to its board of directors following the merger with DiamiR Biosciences Corp, aiming to enhance its strategic initiatives in addressing aging-related diseases [1][3]. Company Overview - Aptorum Group is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic assets for unmet medical needs, particularly in oncology and infectious diseases [8]. - DiamiR Biosciences is a private molecular diagnostics company that develops minimally invasive tests for early detection and monitoring of brain health conditions, utilizing a proprietary platform technology based on microRNA signatures [9]. Leadership Changes - Dr. Laura A. Philips, co-founder and CEO of Spheryx, Inc., joins Aptorum's board as an independent director, bringing extensive experience in life sciences and technology [2][3]. - Following the merger, Dr. Kira Sheinerman from DiamiR will join the combined board, and Dr. Alidad Mireskandari will assume the role of President and COO [4][5]. Strategic Goals - The merger is expected to strengthen market awareness and execution capabilities for both Aptorum and DiamiR, particularly in the development of tests for Alzheimer's and other brain diseases [3][4]. - The transaction is anticipated to close in the fourth quarter of 2025, subject to stockholder approval and customary closing conditions [3].

Core Viewpoint - Chinese concept stocks experienced significant gains, with notable increases in share prices for several companies, indicating a positive market sentiment towards these stocks [1] Group 1: Top Gainers - Nature's Sunshine Products (UPC) saw a remarkable increase of 82.98%, closing at a price of 9.460, with a trading volume of 235 million [1] - Melco Resorts & Entertainment (MSC) rose by 19.23%, reaching a price of 4.680, with a trading volume of 48,500 [1] - I-Mab (IMAB) increased by 16.02%, closing at 5.070, with a trading volume of 29.76 million [1] - Zai Lab (APM) experienced a gain of 15.31%, closing at 2.410, with a trading volume of 1.6078 million [1] - China Natural Resources (CHNR) rose by 14.84%, closing at 5.700, with a trading volume of 8.8604 million [1]

NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a joint presentation at the H.C. Wainwright 27th Annual Global Investment Conference (https://hcwevents.com/annualconferen ...

Core Viewpoint - Chinese concept stocks experienced significant declines, with the top five losers showing steep drops in their stock prices, indicating potential market volatility and investor concerns [1] Group 1: Stock Performance - Dongfang Culture (OCG) saw a decline of 17.19%, closing at 2.890, with a trading volume of 585,300 [1] - Renkong Technology (RCON) dropped by 12.69%, ending at 2.270, with a trading volume of 1,132,700 [1] - Zhiling Group (APM) fell by 11.74%, closing at 2.330, with a trading volume of 6,809,100 [1] - Luda Technology (LUD) decreased by 10.66%, finishing at 5.280, with a trading volume of 75,800 [1] - Dingxin Holdings (DXST) experienced a drop of 10.31%, closing at 1.130, with a trading volume of 60,800 [1]

| 代码 | 名称 | 最新价 | 涨跌幅√ | 涨跌额 | 成交额 | | --- | --- | --- | --- | --- | --- | | APM | 知临集团 | 4.250 | 234.65% | +2.980 | 12.82亿 | | LUD | 禄达技术 | 6.520 | 49.89% | +2.170 | 109.79万 | | DDC | 日日煮 | 13.450 | 28.83% | +3.010 | 286.97万 | | DKI | 黑瞳科技 | 4.500 | 24.14% | +0.875 | 131.55万 | | STAK | 斯塔克工业 | 1.730 | 20.98% | +0.300 | 455.84万 | 中概股收盘涨幅前五的个股为：知临集团涨234.65%，禄达技术涨49.89%，日日煮涨28.83%，黑瞳科技 涨24.14%，斯塔克工业涨20.98%。(格隆汇) ...

Aptorum Group Limited APM stock is trading higher on Thursday, with a robust session volume of 168.16 million compared to the average volume of 3.25 million, as per data from Benzinga Pro. Its merger partner, DiamiR Biosciences Corp., received a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health (NYSDOH). Also Read: Thermo Fisher Positioned As Biopharma's Partner Of Choice This milestone allows DiamiR to offer its validated A ...

作者：行情君 资料显示，知临集团有限责任公司(Nasdaq:APM)是一家生物制药企业致力推进一系列崭新医疗及诊断 科技的研发和商品化以应对未被满足的医疗需求。知临集团当前的药品开发项目包括孤儿疾病,传染病 和代谢性疾病的适应症,其中一些项目目标于2020年进入临床试验阶段。知临集团还经营着一家女性保 健品业务,其DioscoreaOpposita生物活性营养片剂目前正在商业化。 本文源自：金融界 8月21日，知临集团(APM)开盘上涨123.62%，截至21:30，报2.84美元/股，成交2.53亿美元，总市值 2028.83万美元。 财务数据显示，截至2023年12月31日，知临集团收入总额43.14万美元，同比减少66.71%；归母净利 润-282.46万美元，同比增长71.18%。 ...